Endogenous Depression disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: END040 MIFTS: 53	Endogenous Depression Categories: Mental diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Endogenous Depression

MalaCards integrated aliases for Endogenous Depression:

Name: Endogenous Depression ¹¹ ¹⁴ ⁷¹ ⁷⁵

Unipolar Depression ¹¹ ¹⁴ ⁷¹

Clinical Depression ¹¹ ⁵³ ⁷¹

Depressive Disorder ⁴³ ⁷¹

Classifications:

MalaCards categories:
Anatomical: Mental diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:1595

MeSH ⁴³ D003866

NCIt ⁴⁹ C34532 C35094

SNOMED-CT ⁶⁸ 191599006

UMLS ⁷¹ C0011573 C0011581 C0041696 more

Sources

Summaries for Endogenous Depression

Disease Ontology: ¹¹ A mental depression that is characterized by a dysregulation of the endogenous opioid system and not of the monaminergic system.

MalaCards based summary: Endogenous Depression, also known as unipolar depression, is related to major depressive disorder and diarrhea, and has symptoms including depressed - symptom An important gene associated with Endogenous Depression is TRH (Thyrotropin Releasing Hormone), and among its related pathways/superpathways are GPCR downstream signalling and Signal Transduction. The drugs Parathyroid hormone and Valsartan have been mentioned in the context of this disorder. Affiliated tissues include brain, prefrontal cortex and cortex, and related phenotypes are nervous system and homeostasis/metabolism

Wikipedia: ⁷⁵ Endogenous depression (melancholia) is an atypical sub-class of major depressive disorder (clinical... more...

Sources

Related Diseases for Endogenous Depression

Diseases related to Endogenous Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 872)

#	Related Disease	Score	Top Affiliating Genes
1	major depressive disorder	31.0	TTC9B TRH TPH1 SLC6A4 POMC OXT
2	diarrhea	30.9	TPH1 SLC6A4 IL6 HTR1A BDNF
3	schizoaffective disorder	30.9	SLC6A4 HTR2A HTR1A COMT BDNF
4	postpartum depression	30.8	TTC9B SLC6A4 POMC OXTR OXT NR3C1
5	movement disease	30.7	HTR2A HTR1A H2AC18 COMT BDNF
6	vascular dementia	30.7	IL6 HTR1A BDNF
7	back pain	30.7	IL6 CRP BDNF
8	conduct disorder	30.7	TPH1 SLC6A4 POMC OXTR OXT MAOA
9	hyperprolactinemia	30.6	TRH POMC HTR2A GNRH1
10	restless legs syndrome	30.6	SLC6A4 POMC MAOA COMT
11	intracranial hypertension	30.6	POMC IL6 CRP
12	parkinson disease, late-onset	30.6	TPH1 SLC6A4 MAOA HTR2A HTR1A H2AC18
13	pituitary-dependent cushing's disease	30.5	TRH POMC NR3C1 CRH
14	conn's syndrome	30.5	TRH POMC NR3C1 IL6 GNRH1 CRP
15	body dysmorphic disorder	30.5	SLC6A4 OXT MAOA HTR2A
16	somatization disorder	30.5	SLC6A4 POMC OXT IL6 CRH
17	tobacco addiction	30.5	TPH1 SLC6A4 MAOA HTR2A HTR1A H2AC18
18	antisocial personality disorder	30.5	SLC6A4 OXTR OXT MAOA HTR2A COMT
19	peptic ulcer disease	30.4	IL6 H2AC18 CRP
20	phobia, specific	30.4	SLC6A4 OXT MAOA HTR1A H2AC18 CRH
21	dissociative disorder	30.4	SLC6A4 OXT HTR2A COMT BDNF
22	amnestic disorder	30.4	OXT HTR1A BDNF
23	learning disability	30.4	H2AC18 COMT BDNF
24	paine syndrome	30.4	SLC6A4 POMC IL6 H2AC18 CRH COMT
25	toxic encephalopathy	30.4	IL6 H2AC18 BDNF
26	central diabetes insipidus	30.4	TRH POMC OXT GNRH1
27	conversion disorder	30.4	HTR2A COMT BDNF
28	congenital central hypoventilation syndrome	30.4	SLC6A4 HTR1A BDNF
29	brunner syndrome	30.4	TPH1 SLC6A4 MAOA HTR2A COMT
30	cyclothymic disorder	30.4	SLC6A4 HTR2A HTR1A COMT BDNF
31	chronic pain	30.4	COMT BDNF
32	diabetes insipidus	30.4	POMC OXTR OXT CRH
33	amenorrhea	30.3	TRH POMC OXT GNRH1 CRH
34	cannabis abuse	30.3	SLC6A4 HTR1A COMT BDNF
35	autism spectrum disorder	30.3	SLC6A4 OXTR OXT NR3C1 MAOA IL6
36	cocaine dependence	30.3	SLC6A4 POMC CRH COMT
37	craniopharyngioma	30.3	TRH IL6 GNRH1
38	premenstrual tension	30.3	POMC GNRH1
39	urinary tract infection	30.3	IL6 H2AC18 CRP
40	substance-induced psychosis	30.3	HTR2A HTR1A COMT BDNF
41	neurotic disorder	30.3	SLC6A4 POMC OXT MAOA IL6 HTR2A
42	hypoglycemia	30.3	TRH POMC OXT NR3C1 CRH BDNF
43	acne	30.3	POMC IL6 CRP CRH
44	adult syndrome	30.3	POMC NR3C1 IL6 H2AC18 CRP CRH
45	serotonin syndrome	30.3	SLC6A4 OXT MAOA HTR2A HTR1A
46	premature ovarian failure 7	30.3	POMC CRH
47	sheehan syndrome	30.2	TRH POMC CRH
48	acth deficiency, isolated	30.2	TRH POMC CRH
49	tic disorder	30.2	SLC6A4 MAOA HTR2A HTR1A COMT
50	melancholia	30.2	TRH TPH1 SLC6A4 POMC OXT MAOA

Graphical network of the top 20 diseases related to Endogenous Depression:

Sources

Symptoms & Phenotypes for Endogenous Depression

UMLS symptoms related to Endogenous Depression:

depressed - symptom

GenomeRNAi Phenotypes related to Endogenous Depression according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.2	BDNF COMT CRH CRP EBF1 GNRH1
2	no effect	GR00402-S-2	10.2	BDNF COMT CRH CRP EBF1 GNRH1

MGI Mouse Phenotypes related to Endogenous Depression:

⁴⁵ (show all 11)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	10.32	BDNF COMT CRH EBF1 GNRH1 HTR1A
2	homeostasis/metabolism	MP:0005376	10.31	BDNF COMT CRH CRP GNRH1 HP1BP3
3	growth/size/body region	MP:0005378	10.18	BDNF CRH EBF1 GNRH1 HP1BP3 IL6
4	endocrine/exocrine gland	MP:0005379	10.13	BDNF COMT CRH GNRH1 HTR2A IL6
5	renal/urinary system	MP:0005367	10.06	COMT CRH GNRH1 IL6 NR3C1 OXT
6	no phenotypic analysis	MP:0003012	10.04	BDNF CRH HTR1A NR3C1 OXTR POMC
7	adipose tissue	MP:0005375	9.98	CRH EBF1 IL6 NR3C1 OXT POMC
8	cardiovascular system	MP:0005385	9.93	COMT CRP EBF1 HTR1A IL6 MAOA
9	digestive/alimentary	MP:0005381	9.86	BDNF GNRH1 HTR2A IL6 NR3C1 OXT
10	behavior/neurological	MP:0005386	9.83	BDNF COMT CRH EBF1 HTR1A HTR2A
11	integument	MP:0010771	9.36	BDNF CRH EBF1 GNRH1 IL6 NR3C1

Sources

Drugs & Therapeutics for Endogenous Depression

Drugs for Endogenous Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 624)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Parathyroid hormone

Approved, Investigational

Phase 4

9002-64-6

Valsartan

Approved, Investigational

Phase 4

137862-53-4

60846

Suvorexant

Approved, Investigational

Phase 4

1030377-33-3

57505028 24965990

Oxcarbazepine

Approved

Phase 4

28721-07-5

34312

Scopolamine

Approved, Investigational

Phase 4

51-34-3

153311 3000322

Desipramine

Approved, Investigational

Phase 4

50-47-5

2995

Methadone

Approved

Phase 4

76-99-3, 1095-90-5

4095

Propofol

Approved, Investigational, Vet_approved

Phase 4

2078-54-8

4943

Bromocriptine

Approved, Investigational, Withdrawn

Phase 4

25614-03-3

31101

Atomoxetine

Approved

Phase 4

82248-59-7, 83015-26-3

54841

Doxepin

Approved, Investigational

Phase 4

1668-19-5

667468 667477

Isocarboxazid

Approved

Phase 4

59-63-2

3759

Protriptyline

Approved

Phase 4

438-60-8

4976

Trimipramine

Approved

Phase 4

739-71-9

5584

Tranylcypromine

Approved, Investigational

Phase 4

155-09-9

5530 441233

Ziprasidone

Approved

Phase 4

146939-27-7

60854

Moclobemide

Approved, Investigational

Phase 4

71320-77-9

4235

Maprotiline

Approved, Investigational

Phase 4

10262-69-8

4011

Topiramate

Approved

Phase 4

97240-79-4

5284627

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Simvastatin

Approved

Phase 4

79902-63-9

54454

Buprenorphine

Approved, Illicit, Investigational, Vet_approved

Phase 4

52485-79-7, 53152-21-9

644073 40400

Ribavirin

Approved

Phase 4

36791-04-5

37542

Pioglitazone

Approved, Investigational

Phase 4

111025-46-8

4829

Eszopiclone

Approved, Investigational

Phase 4

138729-47-2

969472

Memantine

Approved, Investigational

Phase 4

41100-52-1, 19982-08-2

4054

Calcium carbonate

Approved, Investigational

Phase 4

471-34-1

Diphenhydramine

Approved, Investigational

Phase 4

147-24-0, 58-73-1

3100

Promethazine

Approved, Investigational

Phase 4

60-87-7

4927

Nefazodone

Approved, Withdrawn

Phase 4

82752-99-6, 83366-66-9

4449

Modafinil

Approved, Investigational

Phase 4

68693-11-8

4236

Riluzole

Approved, Investigational

Phase 4

1744-22-5

5070

Buspirone

Approved, Investigational

Phase 4

36505-84-7

2477

Acamprosate

Approved, Investigational

Phase 4

77337-73-6, 77337-76-9

71158

Curcumin

Approved, Investigational

Phase 4

458-37-7, 84765-67-3

969516

Metamfetamine

Approved, Illicit, Withdrawn

Phase 4

537-46-2

10836

Iloperidone

Approved

Phase 4

133454-47-4

71360

Medroxyprogesterone acetate

Approved, Investigational

Phase 4

520-85-4, 71-58-9

6279 10631

Losartan

Approved

Phase 4

114798-26-4

3961

Exenatide

Approved, Investigational

Phase 4

141758-74-9

45588096

Zolpidem

Approved

Phase 4

82626-48-0

5732

Raloxifene

Approved, Investigational

Phase 4

82640-04-8, 84449-90-1

5035

Alendronic acid

Approved

Phase 4

121268-17-5, 66376-36-1

2088

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Bazedoxifene

Approved, Investigational

Phase 4

198481-32-2

154257

Carbamazepine

Approved, Investigational

Phase 4

298-46-4

2554

Hyaluronic acid

Approved, Vet_approved

Phase 4

9004-61-9

53477741

Donepezil

Approved

Phase 4

120014-06-4

3152

Naloxone

Approved, Vet_approved

Phase 4

465-65-6

5284596

Fluticasone

Approved, Experimental

Phase 4

90566-53-3

4659387 5311101

Interventional clinical trials:

(show top 50) (show all 4779)

#	Name	Status	NCT ID	Phase	Drugs
1	THE AIUNI - Integral Assessment in Unipolar Depression	Unknown status	NCT02268487	Phase 4	Sertraline
2	Phase 4 Study of Vitamin D3 Supplementation for Outcomes in Patients With Unipolar Depression	Unknown status	NCT01390662	Phase 4
3	Personalized Indications for Cognitive Behavioural Therapy and Antidepressants in the Treatment of Major Depressive Disorder and Persistent Depressive Disorder	Unknown status	NCT02752542	Phase 4	Pharmacotherapy
4	International Study to Predict Optimised Treatment - in Depression	Unknown status	NCT00693849	Phase 4	Escitalopram;Sertraline;Venlafaxine-XR
5	Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder	Unknown status	NCT01699490	Phase 4	Fluoxetine + Valsartan;Fluoxetine + Placebo
6	Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label	Unknown status	NCT00650897	Phase 4	Escitalopram
7	D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression	Unknown status	NCT02772211	Phase 4	Ketamine;D-cycloserine;Placebo
8	Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR)	Unknown status	NCT02711215	Phase 4	Citalopram;Escitalopram (Mirtazapine/Duloxetine/Venlafaxine);Placebo
9	A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia	Unknown status	NCT02669030	Phase 4	suvorexant;Placebo
10	Clinical Trial of the Use of Ketamine in Treatment Resistant Depression	Unknown status	NCT02610712	Phase 4	Ketamine
11	Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder	Unknown status	NCT02294305	Phase 4	Vortioxetine;Placebo
12	Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder	Unknown status	NCT00442481	Phase 4	Escitalopram
13	Ketamine Enhancement of rTMS for Refractory Depression	Unknown status	NCT04352621	Phase 4	intranasal ketamine
14	Phase 4 Study of Escitalopram Treatment and Biomarkers in Major Depressive Disorder	Unknown status	NCT01997580	Phase 4	escitalopram
15	A Multicenter, 52-week, Provider- Randomized, Pragmatic Trial to Assess the Differences in ABILIFY MYCITE - a Digital Medicine System (DMS) Versus Treatment as Usual (TAU) for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole	Unknown status	NCT03881449	Phase 4
16	Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder	Unknown status	NCT02273154	Phase 4	Buspirone;Paroxetine
17	A Prospective Post Marketing Surveillance Study Study for the Evaluation of the Safety and Efficacy of the Predictix Antidepressant (PAD) Clinician Software Support Tool in Prescribing Antidepressant Medication/s for the Treatment of Patients Suffering From Major Depressive Disorder	Unknown status	NCT04138290	Phase 4
18	Cognitive Dysfunction in Patients With Major Depressive Disorder, Clinical Peculiarities, Biological Markers, and Treatment Efficacy	Unknown status	NCT03187093	Phase 4	Vortioxetine;Escitalopram
19	Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis	Unknown status	NCT02330679	Phase 4	Desvenlafaxine;Placebo
20	Multi-dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics	Unknown status	NCT03219008	Phase 4	Fluoxetine;fluoxetine + Amfebutamone;Fluvoxamine;Lithium+fluvoxamine;Mirtazapine/SNRIs;mirtazapine + SNRIs
21	Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder	Unknown status	NCT02346682	Phase 4	venlafaxine
22	Ketamine Co-induction for Patients With Major Depressive Disorder; a Randomized Clinical Trial	Unknown status	NCT03666494	Phase 4	Ketamine Hydrochloride;Propofol;Fentanyl
23	Brain Mechanisms and Targeting Insomnia in Major Depression	Unknown status	NCT00628914	Phase 4	escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
24	A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression.	Unknown status	NCT00335205	Phase 4	ropinirole
25	Phase 4 Study on the Effect of Partial Sleep Deprivation on Cognition and the IL-6-gp130-System in Individuals With Major Depression	Unknown status	NCT00291239	Phase 4
26	Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial	Unknown status	NCT00209807	Phase 4	escitalopram;Reboxetine
27	The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders	Unknown status	NCT03122158	Phase 4	Escitalopram
28	Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life	Unknown status	NCT00889369	Phase 4	Duloxetine
29	Interactions Between The Serotonin Transporter And Sympathetic Nervous System Activation In Patients With Major Depressive Disorder - Understanding The Link Between The Brain And The Heart	Unknown status	NCT01568307	Phase 4	Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.
30	A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder.	Unknown status	NCT01483053	Phase 4	Agomelatine;Escitalopram
31	Algorithm Guided Treatment Strategies for Major Depressive Disorder	Unknown status	NCT01764867	Phase 4	Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Bupropion;Trazodone
32	Pharmacogenomics Studies of Antidepressants	Unknown status	NCT01204086	Phase 4	Venlafaxine;Fluoxetine
33	The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope	Unknown status	NCT01357967	Phase 4	SSRI monotherapy;Seroquel XR adjunctive
34	Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study	Unknown status	NCT01391221	Phase 4	Duloxetine
35	White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study	Unknown status	NCT01492621	Phase 4	Desvenlafaxine
36	Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder	Unknown status	NCT01460212	Phase 4	SSRI antidepressants
37	Prospective 24-week Study, Comparing Clinical Outcomes Between Switching Antidepressants and Maintaining the Same Antidepressant in Patients With Major Depressive Disorder Who do Not Show a 20% Reduction in Symptoms at Week 2	Unknown status	NCT00519012	Phase 4	Sertraline to Paroxetine;Paroxetine to Sertraline
38	A Prospective, Single-Blinded, Randomized, Multicentre Study to Evaluate the Utility, Safety, and Efficacy of Using PEER Interactive to Inform the Prescription of Medications to Subjects With a Primary Diagnosis of a Depressive Disorder	Unknown status	NCT04620499	Phase 4
39	Agomelatine Added to SSRIs or SNRIs for Early-nonresponsive Patients With Major Depressive Disorder: a Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial	Unknown status	NCT04589143	Phase 4	Agomelatine;Placebos
40	A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Major Depressive Disorder (MDD)	Unknown status	NCT01556971	Phase 4	Botox;Saline Solution
41	Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder	Unknown status	NCT02213016	Phase 4
42	Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder	Unknown status	NCT02924090	Phase 4	Etomidate;Ketamine
43	Intramuscular Ketamine Versus Escitalopram and Aripiprazole in Acute and Maintenance Treatment of Patients With Treatment-resistant Depression	Unknown status	NCT04234776	Phase 4	Ketamine
44	Turgut Ozal Medical Center Department of Anesthesiology and Reanimation	Unknown status	NCT02267980	Phase 4	Sevoflurane;Ketamine;Saline
45	Objective to Evaluate the Efficacy and Safety of Peropirone Hydrochloride Tablets in the Treatment of Adolescent Bipolar Depressive Episode: a Multicenter Open Randomized Controlled Clinical Trial	Unknown status	NCT04826510	Phase 4	Perospirone hydrochloride tablets;Lithium carbonate + perospirone hydrochloride;Lithium Carbonate Pill
46	Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression.	Unknown status	NCT03491696	Phase 4	Metyrapone
47	Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child	Unknown status	NCT01796132	Phase 4	SSRI/SNRI
48	The Assessment of Osteoporosis Treatment in Post-menopausal Women	Unknown status	NCT03006003	Phase 4	Raloxifene;Alendronate
49	Randomized Trial Evaluating the Effectiveness of MYnd Analytics Directed Therapy in Depression	Unknown status	NCT03328052	Phase 4
50	A 12 Week, Open Label, Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression	Unknown status	NCT01974934	Phase 4	Desvenlafaxine Succinate

Search NIH Clinical Center for Endogenous Depression

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Alprazolam

Amitriptyline

Amitriptyline Hydrochloride

Amoxapine

Bupropion

Bupropion hydrobromide

Bupropion Hydrochloride

Buspirone

buspirone hydrochloride

Citalopram

Citalopram hydrobromide

Clomipramine

Clomipramine Hydrochloride

Desipramine

Desipramine Hydrochloride

Doxepin

Doxepin Hydrochloride

Escitalopram

Escitalopram oxalate

Fluoxetine

Fluoxetine Hydrochloride

Fluvoxamine

Fluvoxamine Maleate

HYPERICUM PERFORATUM (ST. JOHN'S WORT)

Imipramine

Imipramine Hydrochloride

Imipramine pamoate

Isocarboxazid

Isoflurane

Kava preparation

Lithium

Lithium Aspartate

Lithium Carbonate

lithium citrate

Lorazepam

Maprotiline

Maprotiline Hydrochloride

Methylphenidate

Methylphenidate Hydrochloride

Mirtazapine

nefazodone

Nortriptyline

Nortriptyline Hydrochloride

Paroxetine

Paroxetine Hydrochloride

Phenelzine

Phenelzine Sulfate

Pramipexole

Pramipexole dihydrochloride

Protriptyline

Protriptyline Hydrochloride

Selegiline

selegiline hydrochloride

Sertraline

Sertraline Hydrochloride

Temazepam

Tranylcypromine

Tranylcypromine sulfate

Trazodone

Trazodone Hydrochloride

Tricyclic Antidepressant [EPC]

Trimipramine

Trimipramine Maleate

venlafaxine

Venlafaxine hydrochloride

Cochrane evidence based reviews: depressive disorder

Sources

Genetic Tests for Endogenous Depression

Sources

Anatomical Context for Endogenous Depression

Organs/tissues related to Endogenous Depression:

MalaCards : Brain, Prefrontal Cortex, Cortex, Pituitary, Temporal Lobe, Heart, Cingulate Cortex

Sources

Publications for Endogenous Depression

Articles related to Endogenous Depression:

(show top 50) (show all 7085)

#	Title	Authors	PMID	Year
1	Upregulation of serotonin transporter by alcohol in human dendritic cells: possible implication in neuroimmune deregulation. ⁵³ ⁶²	Babu DK...Nair MP	19572987	2009
2	Pharmacogenetic insights to monoaminergic dysfunction in alcohol dependence. ⁵³ ⁶²	Heinz A...Puls I	15148564	2004
3	Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. ⁵³ ⁶²	Serebruany VL...O'Connor CM	12960610	2003
4	Relationship between cortisol and serotonin metabolites and transporters in alcoholism [correction of alcolholism]. ⁵³ ⁶²	Heinz A...Weinberger DR	12163982	2002
5	Different effects of pyridostigmine on the thyrotropin response to thyrotropin-releasing hormone in endogenous depression and subclinical thyrotoxicosis. ⁵³ ⁶²	Coiro V...Chiodera P	9440477	1998
6	Suicide: a four-pathway clinical-biochemical model. ⁵³ ⁶²	Fawcett J...Fogg L	9616805	1997
7	Beta-lipotropin-beta-endorphin response to low-dose ovine corticotropin releasing factor in endogenous depression. Preliminary studies. ⁵³ ⁶²	Young EA...Akil H	2139563	1990
8	Neuroendocrine aspects of primary endogenous depression. X: Serum growth hormone measures in patients and matched control subjects. ⁵³ ⁶²	Rubin RT...Lesser IM	2111183	1990
9	Whole blood mitochondrial DNA copy number in depression and response to electroconvulsive therapy. ⁶²	Ryan KM...McLoughlin DM	36216200	2023
10	Convergent and divergent cognitive impairment of unipolar and bipolar depression: A magnetoencephalography resting-state study. ⁶²	Wang H...Lu Q	36181913	2023
11	Recent advances in sleep and depression. ⁶²	Mirchandaney R...Kaplan KA	36449730	2023
12	The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. ⁶²	Rosenblat JD...Taylor V	35975555	2023
13	The centrality of working memory networks in differentiating bipolar type I depression from unipolar depression: A task-fMRI study. ⁶²	Xi C...Palaniyappan L	35244484	2023
14	Circuit-wide proteomics profiling reveals brain region-specific protein signatures in the male WKY rats with endogenous depression. ⁶²	Liao J...Zhang J	36162674	2023
15	Heterotopic 4T1 breast cancer transplantation induces hippocampal inflammation and depressive-like behaviors in mice. ⁶²	Yan W...Ren Z	35947291	2022
16	A broken circadian clock: The emerging neuro-immune link connecting depression to cancer. ⁶²	Su K...Liu Q	36281466	2022
17	Immune system disruptions implicated in whole blood epigenome-wide association study of depression among Parkinson's disease patients. ⁶²	Paul KC...Ritz B	36325427	2022
18	Electroconvulsive Therapy for Unipolar Depression in Older Adults: Overall Outcomes and Clinical Trajectories of Nonresponders. ⁶²	Morcos N...Strominger J	35462391	2022
19	Astrocytes and major depression: The purinergic avenue. ⁶²	Zhao YF...Illes P	36122663	2022
20	The association of exposure to air pollution and depression in women; a cross-sectional study of a middle-income country. ⁶²	Khosrorad R...Miri M	36075476	2022
21	A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial. ⁶²	Price RB...Howland RH	36128684	2022
22	Associations between children's diagnosed mental disorders and educational achievements in Sweden. ⁶²	Bortes C...Strandh M	35416111	2022
23	Mid- and Late-Life Physical Activity and Neuropsychiatric Symptoms in Dementia-Free Older Adults: Mayo Clinic Study of Aging. ⁶²	Krell-Roesch J...Geda YE	36464975	2022
24	Treatment patterns and healthcare utilization of patients with treatment-resistant depression estimated using health insurance database: A population-based study from Taiwan. ⁶²	Huang WL...Tang CH	36096374	2022
25	Early-Onset Type 2 Diabetes and Mood, Anxiety, and Stress-Related Disorders: A Genetically Informative Register-Based Cohort Study. ⁶²	Liu S...Butwicka A	36251507	2022
26	[Multidimensional and computational theory of mood]. ⁶²	Bottemanne H...Fossati P	35987716	2022
27	A longitudinal study of restless legs symptoms among patients with depression. ⁶²	Auvinen P...Mantyselka P	35191781	2022
28	Effects of emotional contexts on respiratory attention task performance. ⁶²	Chan PS...Davenport PW	36368617	2022
29	The use of electroconvulsive therapy (ECT) en bloc in Denmark: a nationwide register-based study. ⁶²	Pedersen MI...Ostergaard SD	36344233	2022
30	Neurovascular alterations in bipolar disorder: A review of perfusion weighted magnetic resonance imaging studies. ⁶²	Delvecchio G...Brambilla P	35940377	2022
31	Effectiveness of social support-based interventions in preventing depression in people without clinical depression: A systematic review and meta-analysis of randomized controlled trials. ⁶²	Campos-Paino H...Bellon JA	36419332	2022
32	The Emotion-Regulation Benefits of Implicit Reappraisal in Clinical Depression: Behavioral and Electrophysiological Evidence. ⁶²	Yuan J...Zhang D	36355339	2022
33	Effectiveness and safety of monoamine oxidase inhibitor treatment for bipolar depression versus unipolar depression: An exploratory case cohort study. ⁶²	Kim TT...Amsterdam JD	36331516	2022
34	Association Between Polygenic Risk Scores and Outcome of ECT. ⁶²	Sigstrom R...Landen M	36069021	2022
35	The sociodemographic characteristics and clinical features of the late-life depression patients: results from the Beijing Anding Hospital mental health big data platform. ⁶²	Wang X...Zhang Q	36324116	2022
36	Depression in healthcare workers: Results from the nationwide AMADEUS survey. ⁶²	Fond G...Boyer L	35952535	2022
37	Mental health and behavioural problems in adolescents conceived after ART. ⁶²	Wijs LA...Hart RJ	36166695	2022
38	[Feasibility, Practicability, and Acceptance of Outpatient Psychotherapy for Home-living Older Adults with Depression in Need of Care in Germany]. ⁶²	Tegeler C...Kessler EM	36417929	2022
39	Effects of Physical Activity Interventions in the Elderly with Anxiety, Depression, and Low Social Support: A Clinical Multicentre Randomised Trial. ⁶²	Ruiz-Comellas A...Vidal-Alaball J	36360543	2022
40	Affective working memory in depression. ⁶²	Songco A...Schweizer S	36441997	2022
41	Reduced neural responses to reward reflect anhedonia and inattention: an ERP study. ⁶²	Liu Z...Zhang Z	36261598	2022
42	Pain, Anxiety, and Depression in Patients Undergoing Chronic Hemodialysis Treatment: A Multicentre Cohort Study. ⁶²	Masia-Plana A...Mantas-Jimenez S	35466067	2022
43	Exploring antiretroviral therapy adherence, competing needs, and viral suppression among people living with HIV and food insecurity in the Dominican Republic. ⁶²	Derose KP...Wagner G	34581230	2022
44	The importance for wellbeing of having views of nature from and in the home during the COVID-19 pandemic. Results from the GreenCOVID study. ⁶²	Garrido-Cumbrera M...Hewlett D	35991355	2022
45	A systematic review, meta-analysis, and meta-regression of patient education for secondary prevention in patients with coronary heart disease: impact on psychological outcomes. ⁶²	Shi W...Gallagher R	35134883	2022
46	Navigating the Storm to Recovery through the Pictorial Representations of Persons in the Recovery Phase from Unipolar Depression. ⁶²	Scerri J...Bonnici A	36294007	2022
47	Current Perspectives on Pharmacological and Non-Pharmacological Interventions for the Inflammatory Mechanism of Unipolar Depression. ⁶²	Dogaru IA...Dionisie V	36291336	2022
48	Depression in primary care and the role of evidence-based guidelines: cross-sectional data from primary care physicians in Germany. ⁶²	Lech S...Buspavanich P	36280876	2022
49	Working memory updating in individuals with bipolar and unipolar depression: fMRI study. ⁶²	Manelis A...Phillips ML	36220840	2022
50	Adapted Behavioural Activation for Bipolar Depression: A Randomised Multiple Baseline Case Series. ⁶²	Wright K...Thomas Z	36291340	2022

Sources

Genes for Endogenous Depression

Genes related to Endogenous Depression (0 elite genes):

(show all 35)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	TRH	Thyrotropin Releasing Hormone	Protein Coding	16.69	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9440477 2111183
2	MAOA	Monoamine Oxidase A	Protein Coding	13.31	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19572987
3	CRH	Corticotropin Releasing Hormone	Protein Coding	12.43	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9616805 2139563
4	GNRH1	Gonadotropin Releasing Hormone 1	Protein Coding	11.03	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
5	SLC6A4	Solute Carrier Family 6 Member 4	Protein Coding	10.91	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12163982 15148564
6	OXT	Oxytocin/Neurophysin I Prepropeptide	Protein Coding	8.3	DISEASES inferred ¹⁴
7	BDNF	Brain Derived Neurotrophic Factor	Protein Coding	8.04	DISEASES inferred ¹⁴
8	HTR1A	5-Hydroxytryptamine Receptor 1A	Protein Coding	7.5	DISEASES inferred ¹⁴
9	TTC9B	Tetratricopeptide Repeat Domain 9B	Protein Coding	7.4	DISEASES inferred ¹⁴
10	OXTR	Oxytocin Receptor	Protein Coding	7.4	DISEASES inferred ¹⁴
11	POMC	Proopiomelanocortin	Protein Coding	7.25	DISEASES inferred ¹⁴
12	NR3C1	Nuclear Receptor Subfamily 3 Group C Member 1	Protein Coding	7.09	DISEASES inferred ¹⁴
13	IL6	Interleukin 6	Protein Coding	7	DISEASES inferred ¹⁴
14	HTR2A	5-Hydroxytryptamine Receptor 2A	Protein Coding	6.9	DISEASES inferred ¹⁴
15	HP1BP3	Heterochromatin Protein 1 Binding Protein 3	Protein Coding	6.85	DISEASES inferred ¹⁴
16	CRP	C-Reactive Protein	Protein Coding	6.8	DISEASES inferred ¹⁴
17	H2AC18	H2A Clustered Histone 18	Protein Coding	6.67	DISEASES inferred ¹⁴ ¹⁴
18	COMT	Catechol-O-Methyltransferase	Protein Coding	6.61	DISEASES inferred ¹⁴
19	EBF1	EBF Transcription Factor 1	Protein Coding	6.58	DISEASES inferred ¹⁴
20	TPH1	Tryptophan Hydroxylase 1	Protein Coding	6.51	DISEASES inferred ¹⁴
21	CRHR1	Corticotropin Releasing Hormone Receptor 1	Protein Coding	6.51	DISEASES inferred ¹⁴
22	IL1B	Interleukin 1 Beta	Protein Coding	6.45	DISEASES inferred ¹⁴
23	INS	Insulin	Protein Coding	6.43	DISEASES inferred ¹⁴
24	FKBP5	FKBP Prolyl Isomerase 5	Protein Coding	6.41	DISEASES inferred ¹⁴
25	PRL	Prolactin	Protein Coding	6.41	DISEASES inferred ¹⁴
26	TNF	Tumor Necrosis Factor	Protein Coding	6.38	DISEASES inferred ¹⁴
27	TPH2	Tryptophan Hydroxylase 2	Protein Coding	6.29	DISEASES inferred ¹⁴
28	SLC6A3	Solute Carrier Family 6 Member 3	Protein Coding	6.22	DISEASES inferred ¹⁴
29	NTRK2	Neurotrophic Receptor Tyrosine Kinase 2	Protein Coding	6.15	DISEASES inferred ¹⁴
30	CREB1	CAMP Responsive Element Binding Protein 1	Protein Coding	6.13	DISEASES inferred ¹⁴
31	DRD2	Dopamine Receptor D2	Protein Coding	6.11	DISEASES inferred ¹⁴
32	HTR2C	5-Hydroxytryptamine Receptor 2C	Protein Coding	6	DISEASES inferred ¹⁴
33	GABRD	Gamma-Aminobutyric Acid Type A Receptor Subunit Delta	Protein Coding	5.98	DISEASES inferred ¹⁴
34	IL10	Interleukin 10	Protein Coding	5.94	DISEASES inferred ¹⁴
35	GAD2	Glutamate Decarboxylase 2	Protein Coding	5.93	DISEASES inferred ¹⁴

Sources

Variations for Endogenous Depression

Sources

Expression for Endogenous Depression

Search GEO for disease gene expression data for Endogenous Depression.

Sources

Pathways for Endogenous Depression

Pathways related to Endogenous Depression according to GeneCards Suite gene sharing:

(show all 16)

#	Super pathways	Score	Top Affiliating Genes
1	GPCR downstream signalling ⁶⁶ Show member pathways G alpha (i) signalling events ⁶⁶ G alpha (q) signalling events ⁶⁶ Signaling by GPCR ⁶⁶	13.4	TRH POMC OXTR OXT HTR2A HTR1A
2	Signal Transduction ⁶⁶	13.38	TRH TPH1 POMC OXTR OXT NR3C1
3	Class A/1 (Rhodopsin-like receptors) ⁶⁶ Show member pathways GPCR ligand binding ⁶⁶ GPCRs, class A rhodopsin-like ⁷⁴ Peptide GPCRs ⁷⁴ Peptide ligand-binding receptors ⁶⁶	13.19	TRH POMC OXTR OXT HTR2A HTR1A
4	Glucocorticoid receptor regulatory network ⁶¹	11.6	POMC NR3C1 IL6
5	Prader-Willi and Angelman syndrome ⁷⁴	11.45	BDNF GNRH1 OXT POMC
6	Sudden infant death syndrome (SIDS) susceptibility pathways ⁷⁴	11.43	TPH1 SLC6A4 NR3C1 MAOA IL6 HTR2A
7	Biogenic amine synthesis ⁷⁴ Show member pathways Biosynthesis and regeneration of tetrahydrobiopterin and catabolism of phenylalanine ⁷⁴ catecholamine biosynthesis ⁶¹ Catecholamine biosynthesis ⁶⁶ Neurotransmitter disorders ⁷⁴	11.26	TPH1 MAOA COMT
8	Development_Leptin signaling via JAK/STAT and MAPK cascades ²² Show member pathways phospho-PLA2 pathway ⁶⁶	11.09	TRH POMC CRP
9	Serotonin and anxiety ⁷⁴ Show member pathways Serotonin and anxiety-related events ⁷⁴	11.09	POMC HTR2A HTR1A CRH
10	Neurotransmitter clearance ⁶⁶ Show member pathways Dopamine clearance from the synaptic cleft ⁶⁶ Enzymatic degradation of dopamine by COMT ⁶⁶ Enzymatic degradation of Dopamine by monoamine oxidase ⁶⁶ Flavan-3-ol metabolic pathway ⁷⁴ Metabolism of serotonin ⁶⁶ Serotonin clearance from the synaptic cleft ⁶⁶	10.98	SLC6A4 MAOA COMT
11	Methylphenidate Pathway, Pharmacodynamics ⁶⁰ Show member pathways Dopamine receptors ⁶⁶	10.92	SLC6A4 MAOA HTR1A COMT
12	Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics ⁶⁰	10.8	TPH1 SLC6A4 MAOA HTR2A HTR1A
13	Dopamine metabolism ⁷⁴	10.67	MAOA COMT
14	Vasopressin-like receptors ⁶⁶ Show member pathways Defective AVP does not bind AVPR1A,B and causes neurohypophyseal diabetes insipidus (NDI) ⁶⁶ Defective AVP does not bind AVPR2 and causes neurohypophyseal diabetes insipidus (NDI) ⁶⁶	10.59	OXTR OXT
15	Glucocorticoid Pathway (HPA Axis), Pharmacodynamics ⁶⁰	10.36	POMC CRH
16	dopamine degradation ⁶¹	10.19	MAOA COMT

Sources

GO Terms for Endogenous Depression

Biological processes related to Endogenous Depression according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	signal transduction	GO:0007165	10.3	BDNF CRH GNRH1 HTR1A HTR2A IL6
2	eating behavior	GO:0042755	9.91	TRH OXTR OXT
3	serotonin receptor signaling pathway	GO:0007210	9.81	HTR2A HTR1A
4	negative regulation of gastric acid secretion	GO:0060455	9.8	OXTR OXT
5	positive regulation of penile erection	GO:0060406	9.78	OXTR OXT
6	positive regulation of norepinephrine secretion	GO:0010701	9.76	OXTR OXT
7	maternal behavior	GO:0042711	9.73	OXTR OXT NR3C1
8	response to steroid hormone	GO:0048545	9.71	OXTR OXT GNRH1
9	sleep	GO:0030431	9.63	OXTR OXT HTR2A
10	behavior	GO:0007610	9.52	HTR2A HTR1A
11	sperm ejaculation	GO:0042713	9.43	SLC6A4 OXTR OXT
12	regulation of digestive system process	GO:0044058	9.32	OXTR OXT
13	memory	GO:0007613	9.32	SLC6A4 OXTR OXT HTR2A BDNF